All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @fitmakayla on TikTok · 29s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @fitmakayla's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I found my retretry tight and pet pet source by doing what you guys are probably doing
  2. 0:04right now, which is trial and error.
  3. 0:06I have tried products that are just shitty and looked in the companies that are really
  4. 0:10shitty.
  5. 0:11There's a lot of scams, a lot of just spun companies out there.
  6. 0:14I found a company that is third party tested, has amazing customer service, posts all their
  7. 0:19purity and test results for all their compounds and has been amazing.
  8. 0:22If you guys want to know that source, just put info in the comments or shoot me a DM.
  9. 0:26I'd be happy to share that info and answer any questions you have.

@fitmakayla's retatrutide sourcing claims need scrutiny

fitmakayla

TikTok creator

86.3K viewsWatch on TikTok

Quick answer

Retatrutide is a triple receptor agonist (GIP, GLP-1, glucagon) currently in Phase 3 clinical trials with no FDA approval or legal consumer availability as of 2024. The creator's video makes no clinical claims but functions as a referral funnel to an unregulated vendor, which presents real safety and legal risks to viewers seeking this compound. Any retatrutide sold outside a clinical trial context is an unverified research chemical with no guaranteed purity, sterility, or accurate dosing.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @fitmakayla's retatrutide sourcing claims need scrutiny, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@fitmakayla's retatrutide sourcing claims need scrutiny is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@fitmakayla's retatrutide sourcing claims need scrutiny" from fitmakayla. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Retatrutide is a triple receptor agonist (GIP, GLP-1, glucagon) currently in Phase 3 clinical trials with no FDA approval or legal consumer availability as of 2024.

The reason this review is not generic is the source wording and the canonical claim label "peptides don t know where to get r3tatrutide or peptides i got you co." In this clip, the useful excerpt is: "I found my retretry tight and pet pet source by doing what you guys are probably doing right now, which is trial and error." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Phase 2 data (Jastreboff et al.
People who land here are usually trying to understand whether the Peptide social video fact-checks claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Retatrutide is a triple receptor agonist (GIP, GLP-1, glucagon) currently in Phase 3 clinical trials with no FDA approval or legal consumer availability as of 2024.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Retatrutide is a triple receptor agonist (GIP, GLP-1, glucagon) currently in Phase 3 clinical trials with no FDA approval or legal consumer availability as of 2024. The creator's video makes no clinical claims but functions as a referral funnel to an unregulated vendor, which presents real safety and legal risks to viewers seeking this compound. Any retatrutide sold outside a clinical trial context is an unverified research chemical with no guaranteed purity, sterility, or accurate dosing.
  • Retatrutide is not FDA-approved and has no legal consumer purchase pathway as of 2024. It exists only in Eli Lilly's clinical trial program.
  • Phase 2 data (Jastreboff et al., 2023, NEJM) showed up to 24.2% weight loss over 48 weeks, but that was pharmaceutical-grade drug under clinical monitoring, not a vendor product.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Retatrutide is not FDA-approved and has no legal consumer purchase pathway as of 2024. It exists only in Eli Lilly's clinical trial program.
  • Phase 2 data (Jastreboff et al., 2023, NEJM) showed up to 24.2% weight loss over 48 weeks, but that was pharmaceutical-grade drug under clinical monitoring, not a vendor product.
  • Third-party certificates of analysis for gray-market peptides frequently omit endotoxin, sterility, and residual solvent testing, all critical for injectables.
  • A 2022 Valisure analysis found meaningful quality and potency inconsistencies across gray-market peptide products, consistent with the creator's acknowledgment that scams are common.
  • Social media referral funnels for unregulated compounds shift legal and health risk entirely onto the buyer. The vendor and the influencer face different exposure than the person injecting an unknown compound.
  • Legal, supervised options for GLP-1 class therapy exist through licensed telehealth providers and 503A/503B pharmacies. These involve actual prescriber oversight and verifiable pharmacy licensing.
  • If a vendor is selling retatrutide to consumers today, they are operating outside FDA regulatory frameworks regardless of how professional their website or COA documents appear.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @fitmakayla actually say?

She didn't make clinical claims. She made a sourcing pitch. The video is essentially a funnel: comment "info," get a DM, presumably get a referral link or affiliate code to an unregulated peptide vendor. She frames it as helpfulness, saying she found her source through "trial and error" and that it's "third party tested" with posted purity results. That's the whole argument. No efficacy claims, no dosing advice, just a trust signal built around vendor vetting credentials she can't actually verify for you.

To her credit, she acknowledged that the space has "a lot of scams" and "spun companies," which is accurate. But the solution she offers, a DM with a vendor link, doesn't solve that problem. It replaces one unverified source with another unverified source, except this one comes with a social media personality attached.

Does the science back this up?

There's no science to evaluate here, because she made no scientific claims. That's actually worth flagging. Retatrutide (LY3437943), the compound she appears to be referencing, is a triple GIP/GLP-1/glucagon receptor agonist developed by Eli Lilly. It's in Phase 3 trials as of 2024. It is not FDA-approved. It is not commercially available through any legitimate channel.

A 2023 Phase 2 trial published in The New England Journal of Medicine (Jastreboff et al., 2023) showed retatrutide produced up to 24.2% body weight reduction over 48 weeks in adults with obesity. Those results are real and notable. But that trial used pharmaceutical-grade retatrutide manufactured under strict controls, administered by clinicians, with safety monitoring. Whatever a TikTok DM vendor is selling under that name is not that product. There is no regulatory pathway for a consumer to legally obtain retatrutide right now, period.

What did they get wrong (or right)?

She got one thing right: the gray-market peptide space is full of scams and low-quality products. A 2022 analysis by Valisure found significant quality and potency inconsistencies across compounded and gray-market peptide products. The problem of "spun companies" and mislabeled compounds is documented and real.

What she got wrong is the implied solution. "Third party tested" sounds rigorous, but in the unregulated research chemical market, third-party certificates of analysis are frequently incomplete, outdated, or issued by labs with no accreditation. A COA confirming peptide identity doesn't tell you about bacterial endotoxins, residual solvents, or sterility, all of which matter if someone is injecting this. She also sidesteps the legal reality entirely. Selling retatrutide to consumers in the U.S. without a prescription and without FDA approval is not a gray area. It's a federal legal exposure for the vendor and a health risk for the buyer. Framing this as a helpful community resource obscures that entirely.

What should you actually know?

If you're interested in GLP-1 class medications, there are legal, medically supervised options available through licensed telehealth platforms. FDA-approved semaglutide and tirzepatide are prescribed by licensed clinicians, dispensed by licensed pharmacies, and come with actual safety oversight. Compounded semaglutide from 503A and 503B pharmacies operates in a specific regulatory framework that has nothing to do with a vendor someone found through TikTok DMs.

Retatrutide specifically doesn't exist in any legitimate consumer channel yet. If someone is selling it, they're selling a research chemical of unknown purity and origin, manufactured outside pharmaceutical standards, with no clinical oversight. The Jastreboff et al. Phase 2 data is genuinely exciting science. But excitement about a drug's trial results is not a reason to inject something sourced from an anonymous vendor a fitness influencer DMed you about.

For any peptide therapy, the relevant questions are: Is the prescriber licensed? Is the pharmacy licensed and inspectable? Is there a real diagnosis and monitoring plan? A TikTok DM answers none of those questions.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

fitmakayla · TikTok creator

86.3K views on this video

Don't know where to get R3tatrutide or peptides I got you comment "info" and I'll DM you

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about retatrutide?

Retatrutide is not FDA-approved and has no legal consumer purchase pathway as of 2024. It exists only in Eli Lilly's clinical trial program.

What does the video say about phase 2 data (jastreboff et al., 2023, nejm) showed up?

Phase 2 data (Jastreboff et al., 2023, NEJM) showed up to 24.2% weight loss over 48 weeks, but that was pharmaceutical-grade drug under clinical monitoring, not a vendor product.

What does the video say about third-party certificates of analysis for gray-market peptides frequently omit endotoxin,?

Third-party certificates of analysis for gray-market peptides frequently omit endotoxin, sterility, and residual solvent testing, all critical for injectables.

What does the video say about a 2022 valisure analysis found meaningful quality?

A 2022 Valisure analysis found meaningful quality and potency inconsistencies across gray-market peptide products, consistent with the creator's acknowledgment that scams are common.

What does the video say about social media referral funnels for unregulated compounds shift legal?

Social media referral funnels for unregulated compounds shift legal and health risk entirely onto the buyer. The vendor and the influencer face different exposure than the person injecting an unknown compound.

What does the video say about legal, supervised options for glp-1 class therapy exist through licensed?

Legal, supervised options for GLP-1 class therapy exist through licensed telehealth providers and 503A/503B pharmacies. These involve actual prescriber oversight and verifiable pharmacy licensing.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by fitmakayla, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.